Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

787 results about "Precursor cell" patented technology

In cell biology, a precursor cell, also called a blast cell or simply blast, is a partially differentiated cell, usually referred to as a unipotent cell that has lost most of its stem cell properties. A precursor cell is also known as a progenitor cell but progenitor cells are multipotent. Precursor cells are known as the intermediate cell before they become differentiated after being a stem cell.

Delivery of agents such as cells to tissue

A system for delivering a fluid comprising cells to tissue of a patient includes a container holding an injection fluid and a powered drive. A sensor system provides a measurement indicative of at least shear forces on the cells to a control system. Based at least in part on this measurement, the control system is adapted to transmit a control signal to the powered drive for pressurizing the contents of the container to deposit cells within the tissue of a patient via a fluid path and a patient interface. As an example, the cells can be pregenitor or stem cells.
Owner:BAYER HEALTHCARE LLC

Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells

InactiveUS20060239910A1Improve anti-tumor activityEnhanced antibody-dependent cellular cytotoxicityOrganic active ingredientsNanomedicineDrug specific IgEFolate Receptor Alpha
This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (FRA) and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to FRA-expressing cells as well as in eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer cells; and methods of treating cancer using the antibodies.
Owner:EISAI INC

Bioactive wound dressings and implantable devices and methods of use

The present invention provides wound dressings, optionally surgically implantable, containing biodegradable, polymers and hydrogels having allogenic or autologous precursor cells, such as stem cells and progenitor cells dispersed within. Alternatively, the wound dressings can have conditioned medium obtained from the precursor cells dispersed within. The wound dressings promote tissue restoration processes at a site of application or implantation. Additional bioactive agents can also be dispersed within the polymer / hydrogel matrix, which can be formulated to biodegrade at a controlled rate by adjusting the composition. Methods are also provided for using such biodegradable wound dressings as a delivery device or carrier for the precursor cells, conditioned medium and bioactive agents, or as coatings on implantable medical devices, to promote tissue restoration at a lesion site.
Owner:MEDIVAS LLC

Differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of notch gene

There is provided a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of a Notch gene. Specifically, the invention provides a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells in vitro, which method comprises introducing a Notch gene and / or a Notch signaling related gene into the cells, wherein the finally obtained differentiated cells are the result of cell division of the bone marrow stromal cells into which the Notch gene and / or Notch signaling related gene have been introduced. The invention also provides a method of inducing further differentiation of the differentiation-induced neural cells to dopaminergic neurons or acetylcholinergic neurons. The invention yet further provides a treatment method for neurodegenerative and skeletal muscle degenerative diseases which employs neural precursor cells, neural cells or skeletal muscle cells produced by the method of the invention.
Owner:SANBIO

Modulating immune system development and function through microrna mir-146

InactiveUS20110258716A1Increasing proliferation and activityDecreasing proliferation and activityAnimal cellsAnimal husbandryPrecursor cellOligonucleotide
The present disclosure relates to the finding that microRNA-146 plays a role in modulating the development and function of the immune system. Immune cell development and function can be modulated by delivery of microRNA-146 (miR-146) or antisense miR-146 to target immune cells or precursor cells. For example, in some embodiments, activity and / or proliferation of certain immune cells is regulated by administering miR-146 oligonucleotides or anti-miR-146 oligonucleotides. In other embodiments, pro-inflammatory cytokine expression in immune cells is regulated by administering a miR-146 oligonucleotide or anti-miR-146. In further embodiments, methods of regulating macrophage activity using antisense miR-146 are provided. Additional methods and compositions for regulating immune system function and development using miR-146 are disclosed.
Owner:CALIFORNIA INST OF TECH

Anti-mesothelin antibodies

This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and become internalized by mesothelin-positive cells and also induce an immune effector activity such as antibody dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to mesothelin expressing cells as well as eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to cells expressing the monoclonal antibodies, polyclonal antibodies, antibody derivatives, such as human, humanized, and chimeric monoclonal antibodies, antibody fragments, mammalian cells expressing the monoclonal antibodies, derivatives and fragments, and methods of treating cancer using the antibodies, derivatives and fragments.
Owner:EISAI INC

Method and system for preparing stem cells from fat tissue

The present invention provides a method for preparing homogeneous stem cells and / or precursor cells in a large amount, in a simple and efficient manner, from human (in particular, the subject per se). The present invention further provides a method for preparing tissue implant or graft in a large amount by the use of the stem cells and / or precursor cells of the present invention. The present inventors have unexpectedly discovered that an aspirate from liposuction contains a large number of stem cells and have established a method for preparing stem cells from such an aspirate from liposuction, and thereby achieved the above-mentioned object.
Owner:BIOMASTER

Method for treating a brain cancer with ifenprodil

A clonogenic neurosphere assay is described that carries out high throughput screens (HTS) to identify potent and / or selective modulators of proliferation, differentiation and / or renewal of neural precursor cells, neural progenitor cells and / or self-renewing and multipotent neural stem cells (NSCs). Compositions comprising the identified modulators and methods of using the modulators and compositions, in particular to treat neurological disorders (e.g. brain or CNS cancer) or damage are also disclosed.
Owner:MOUNT SINAI HOSPITAL +1

Methods for immortalizing cells

InactiveUS7399633B2Antibody mimetics/scaffoldsGenetically modified cellsCell Differentiation processCultured cell
The present invention provides methods for immortalizing precursor cells that are non-terminally differentiated cells such as stem cells, said methods comprising culturing the precursor cells in the presence of a Notch agonist and one or more growth factors that support the proliferation but not differentiation of the non-terminally differentiated cells. The present invention further provides methods to induce the differentiation of immortalized cells, comprising growing the cells in the presence of a Notch agonist and at least one growth factor which supports the differentiation of the cell into a more specialized cell type. The immortalized and / or differentiated cells of the invention can be used to repopulate cell populations that have been diminished, for example as a result of infection or exposure to certain drugs. The invention further provides a cell culture comprising a population of non-terminally differentiated cells immortalized by the methods of the present invention and kits comprising reagents that promote the immortalization of precursor cells. The invention further provides methods for screening for Notch modulators and for identifying genes involved in processes of cellular differentiation.
Owner:FRED HUTCHINSON CANCER CENT

Method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of notch gene

There is provided a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of a Notch gene. Specifically, the invention provides a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells in vitro, which method comprises introducing a Notch gene and / or a Notch signaling related gene into the cells, wherein the finally obtained differentiated cells are the result of cell division of the bone marrow stromal cells into which the Notch gene and / or Notch signaling related gene have been introduced. The invention also provides a method of inducing further differentiation of the differentiation-induced neural cells to dopaminergic neurons or acetylcholinergic neurons. The invention yet further provides a treatment method for neurodegenerative and skeletal muscle degenerative diseases which employs neural precursor cells, neural cells or skeletal muscle cells produced by the method of the invention.
Owner:SANBIO

Surgical sutures incorporated with stem cells or other bioactive materials

Materials and Methods for immobilizing bioactive molecules, stem and other precursor cells, and other agents of therapeutic value in surgical sutures and other tissue scaffold devices are described herein. Broadly drawn to the integration and incorporation of bioactive materials into suture constructs, tissue scaffolds and medical devices, the present invention has particular utility in the development of novel systems that enable medical personnel performing surgical and other medical procedures to utilize and subsequently reintroduce bioactive materials extracted from a patient (or their allogenic equivalents) to a wound or target surgical site.
Owner:BIOACTIVE SURGICAL

Gene specifically expressed in postmitotic dopaminergic neuron precursor cells

A novel gene 65B13 expressed specifically and transiently in dopaminergic neuron precursor cells immediately after cell cycle exit was obtained by the present invention. The cellular expression of 65B13 can be used as an index to select cells that are suitable in terms of their safety, survival rate, and network formation ability, for transplant therapy of neurodegenerative diseases such as Parkinson's disease.
Owner:EISIA R&D MANAGEMENT CO LTD

Tissue transplantation compositions and methods

A biomedical material for transplant to a subject is provided according to embodiments of the present invention which includes an isolated donor tissue enzyme-treated to reduce the amount of proteoglycans in the donor tissue compared to untreated tissue. Isolated cells are optionally added to the enzyme-treated donor tissue, including leukocytes, particularly monocytes; macrophages; platelets; cells derived from an intervertebral disc such as chondrocyte-like nucleus pulposus cells; fibrocytes; fibroblasts; mesenchymal stem cells; mesenchymal precursor cells; chondrocytes; or a combination of any of these. The isolated donor tissue is articular cartilage or an intervertebral disc tissue such as nucleus pulposus tissue and / or annulus fibrosis tissue enzyme-treated to remove proteoglycans normally present in these tissues. A biomedical material of the present invention is administered to a subject to treat a disorder or injury, such as a disorder or injury to connective tissue.
Owner:FERREE BRET

Perivascular mesenchymal precursor cell induced blood vessel formation

Mesenchymal precursors cells have been isolated from perivascular niches from a range of tissues utilizing a perivascular marker. A new mesenchymal precursor cell phenotype is described characterized by the presence of the perivascular marker 3G5, and preferably also alpha smooth muscle actin together with early developmental markers such as STRO-1 and CD146 / MUC18. The perivascular mesenchymal precursor cell is shown to induce neovascularisation and improvement in cardiac function. Suitable administration of preparations of the mesenchymal precursor cells are useful for treatment of cardiovascular diseases, cerebrovascular diseases and peripheral vascular diseases.
Owner:MESOBLAST

Induction of Myocardial Cell From Mammalian Bone Marrow Cell or Cord Blood-Derived Cell and Fat Tissue

This invention provides a method for differentiating mammalian bone marrow cells or cord blood-derived cells into myocardial precursor cells and / or myocardial cells by culturing said bone marrow cells or cord blood-derived cells with cells isolated from mammalian fat tissues or a culture supernatant thereof.
Owner:JAPAN SCI & TECH CORP

Perivascular mesenchymal precursor cell induced blood vessel formation

Mesenchymal precursors cells have been isolated from perivascular niches from a range of tissues utilizing a perivascular marker. A new mesenchymal precursor cell phenotype is described characterized by the presence of the perivascular marker 3G5, and preferably also alpha smooth muscle actin together with early developmental markers such as STRO-1 and CD146 / MUC18. The perivascular mesenchymal precursor cell is shown to induce neovascularisation and improvement in cardiac function. Suitable administration of preparations of the mesenchymal precursor cells are useful for treatment of cardiovascular diseases, cerebrovascular diseases and peripheral vascular diseases.
Owner:MESOBLAST

Method and apparatus for cell culture using a two liquid phase bioreactor

Advanced Bioreactor Cell Culture Technology presents a method of cell culturing and bioprocessing incorporating molecular biology techniques, advanced process control methodology, and a process control interface applied to a two liquid phase cell culture bioreactors to proliferate, grow, and expand non-differentiated precursor cells, embryonic stem (ES) cells, endocrine progenitor cells, pancreatic progenitor cells, pancreatic stem cells, pancreatic duct epithelial cells, nestin-positive islet-derived progenitor cells (NIPs), or pluripotent non-embryonic stem (PNES) cells in the bioreactor, and influence, stimulate, and induce the non-differentiated precursors and progenitors into fully differentiated beta cell phenotypes; including microprocessor control of cell culture process variables and data acquisition during bioprocessing. The invention may be applied to precursors and progenitor cells either transgenic or non-transgenic derived from animals and mammals.
Owner:BENEDICT DANIEL J +1

Vascular endothelial growth factor fusion constructs and uses thereof

InactiveUS20050037967A1Inhibiting metastatic spreadInhibiting vascularizationPeptide/protein ingredientsAntibody mimetics/scaffoldsGeloninAbnormal tissue growth
The 121-amino acid isoform of vascular endothelial growth factor (VEGF121) is linked by a flexible G4S tether to a cytotoxic molecule such as toxin gelonin or granzyme B and expressed as a soluble fusion protein. The VEGF12, fusion protein exhibits significant anti-tumor vascular-ablative effects that inhibit the growth of primary tumors and inhibit metastatic spread and vascularization of metastases. The VEGF121 fusion protein also target osteoclast precursor cells in vivo and inhibits osteoclastogenesis.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Stem-cell, precursor cell, or target cell-based treatment of multiorgan failure and renal dysfunction

InactiveUS20070178071A1BiocidePeptide/protein ingredientsMulti organARF - Acute renal failure
Methods for the treatment of acute renal failure, multi-organ failure, early dysfunction of kidney transplant, chronic renal failure, organ dysfunction, and wound healing are provided. The methods include delivering a therapeutic amount of hematopoietic stem cells, non-hematopoietic, mesenchymal stem cells, hemangioblasts, and pre-differentiated cells to a patient in need thereof.
Owner:U S GOVERNMENT REPRESENTED BY THE DEPT OF VETERANS AFFAIRS +1

Modified Vaccinia virus Ankara for the vaccination of neonates

The invention concern the use of a virus for the preparation of a medicament for the vaccination or treatment of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara. In particular, the invention concerns the vaccination of neonates against infections with viruses belonging to the same virus group than the virus used for vaccination. Moreover, the invention concerns the vaccination of neonates against antigens selected from foreign antigens and tumour antigens, wherein the tumour antigen and / or the foreign antigen are different from the antigens associated with the virus. The invention further concerns the use of viruses as defined above to increase the level of factors which activate dendritic cells or their precursor cells and / or to increase the number of dendritic cells or their precursor cells and / or to increase the production and / or cellular content of an interferon (IFN) or IL-12.
Owner:BAVARIAN NORDIC AS

Support for tissue regeneration and process for producing the same

ActiveUS7445793B2Excellent in retention and grafting abilityPrevent intrusionBiocidePowder deliveryFreeze-dryingBiology
The present invention provides a scaffold in which cells can be stably retained and grafted in a uniform distribution state in the culture, preferable proliferation ability and viability can be secured, and particularly in the case of cartilage, fixation treatment such as suture can be carried out in the transplantation into affected parts after the culture, and the mechanical strength is provided sustainable for (weighted) compression at the initial stage of transplantation.The present invention relates to a 3-dimensional porous scaffold for tissue regenerationwhich comprises a structure composed of vertically long-shaped pores having a pore diameter of not less than 10 μm to not more than 500 μm and pore length of not less than 20 μm to not more than 1 cm being juxtaposedly arrangedobtained by a production process comprising rapid freeze-drying as a key technology.Further, the invention relates to the above 3-dimensional porous scaffold in which seeding properties of cells are improved by a pore enlargement treatment of one side face by a separation operation, a salt elution operation of a surface part, or a combination of these operations. It becomes possible to produce a 3-dimensional cell combination having excellent degree of tissue formation and medical treatment effect by seeding a cell or precursor cell derived from a tissue in this scaffold, and culturing them in an artificial environment and / or the living body.
Owner:GC CORP +2

Methods for immortalizing cells

The present invention provides methods for immortalizing precursor cells that are non-terminally differentiated cells such as stem cells, said methods comprising culturing the precursor cells in the presence of a Notch agonist and one or more growth factors that support the proliferation but not differentiation of the non-terminally differentiated cells. The present invention further provides methods to induce the differentiation of immortalized cells, comprising growing the cells in the presence of a Notch agonist and at least one growth factor which supports the differentiation of the cell into a more specialized cell type. The immortalized and / or differentiated cells of the invention can be used to repopulate cell populations that have been diminished, for example as a result of infection or exposure to certain drugs. The invention further provides a cell culture comprising a population of non-terminaly differentiated cells immortalized by the methods of the present invention and kits comprising reagents that promote the immortalization of precursor cells. The invention further provides methods for screening for Notch modulators and for identifying genes involved in processes of cellular differentiation.
Owner:FRED HUTCHINSON CANCER CENT

Transplantable cell growth niche and related compositions and methods

Provided is a method of culturing a successor cell from a precursor cell comprising co-culturing a precursor cell such as, without limitation, a human embryonic stem cell or a neuronal stem cell with an adult mesenchymal stem cell. In one embodiment, the adult mesenchymal stem cell is derived from adipose tissue. Also provided is a composition comprising mesenchymal stem cells in a growth matrix biologically-compatible with the cells. In another embodiment, a method of regenerating tissue is provided comprising introducing into a patient a cell growth niche comprising either or both of mesenchymal stem cells and neuronal stem cell or successor cell in a growth matrix biologically-compatible with the cells. In another embodiment, a method of regenerating tissue is provided comprising introducing into a patient a cell growth niche comprising matrix, cells and slow release polymer beads containing growth factors.
Owner:UNIVERSITY OF PITTSBURGH

Growth of neural precursor cells using umbilical cord blood serum and a process for the preparation thereof for therapeutic purposes

This invention is concerned with stem cells derived from umbilical cord blood serum and a method for growing human embryonic stem cells and adult cells comprising sera separated from clotted umbilical cord blood, including growing and differentiating cord blood stem cells into neural precursors, comprising transdifferentiating CD34+ stem cells from mononuclear cells derived from umbilical cord blood to neural precursors. The stem cells obtained from the umbilical cord include pluripotent stem and progenitor cell population of mononuclear cells, and separating pluripotent stem and progenitor cell population of mononuclear cells obtained from the umbilical cord blood. A magnetic cell separator is used to separate out cells which contain a CD marker and then expanding the cells in a growth medium containing retinoic acid and one or more growth factors BDNF, GDNF, NGF and FGF as a differentiating agent. The invention is also concerned with the transplantation and repair of nerve damage, stokes, spinal injury, Parkinson's and Alzheimer's, prepared in accordance with the aforesaid method and a media for culturing umbilical cord blood stem calls consisting essentially of cord blood stem cells derived from umbilical cord blood serum.
Owner:RELIANCE LIFE SCI PYT

Methods and compositions for culturing endoderm progenitor cells in suspension

Provided herein are methods for the in vitro differentiation of induced pluripotent stem cells, which have been expanded and / or maintained under defined conditions, into endodermal precursor cells (EPCs) that are capable of producing mono-hormonal beta cells.
Owner:FUJIFILM CELLULAR DYNAMICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products